Ruifeng Hu

Dr. Ruifeng Hu

Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
YDYulin Dai
Yulin Dai
RHRuifeng Hu
Ruifeng Hu
ALAndi Liu
Andi Liu
KCKyung Serk Cho
Kyung Serk Cho
AMAstrid Marilyn Manuel
Astrid Marilyn Manuel
ZZZhongming Zhao
Zhongming Zhao
Human complex traits and common diseases show tissue- and cell-type- specificity. Recently, single-cell RNA sequencing (scRNA-seq) technology has successfully depicted cellular heterogeneity in human tissue, providing an unprecedented opportunity to understand the context-specific expression of complex trait-associated genes in human tissue-cell types (TCs). Here, we present the first web-based application to quickly assess the cell-type-specificity of genes, named Web-based Cell-type Specific Enrichment Analysis of Genes (WebCSEA, available at https://bioinfo.uth.edu/webcsea/). Specifically, we curated a total of 111 scRNA-seq panels of human tissues and 1,355 TCs from 61 different general tissues across 11 human organ systems. We adapted our previous decoding tissue-specificity (deTS) algorithm to measure the enrichment for each tissue-cell type (TC). To overcome the potential bias from the number of signature genes between different TCs, we further developed a permutation-based method that accurately estimates the TC-specificity of a given inquiry gene list. WebCSEA also provides an interactive heatmap that displays the cell-type specificity across 1355 human TCs, and other interactive and static visualizations of cell-type specificity by human organ system, developmental stage, and top-ranked tissues and cell types. In short, WebCSEA is a one-click application that provides a comprehensive exploration of the TC-specificity of genes among human major TC map.

19 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PJPeilin Jia
Peilin Jia
RHRuifeng Hu
Ruifeng Hu
GPGuangsheng Pei
Guangsheng Pei
YDYulin Dai
Yulin Dai
YWYin-Ying Wang
Yin-Ying Wang
ZZZhongming Zhao
Zhongming Zhao
Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

2 November 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RHRuifeng Hu
Ruifeng Hu
HXHaodong Xu
Haodong Xu
PJPeilin Jia
Peilin Jia
ZZZhongming Zhao
Zhongming Zhao
Mutations in kinases are abundant and critical to study signaling pathways and regulatory roles in human disease, especially in cancer. Somatic mutations in kinase genes can affect drug treatment, both sensitivity and resistance, to clinically used kinase inhibitors. Here, we present a newly constructed database, KinaseMD (kinase mutations and drug response), to structurally and functionally annotate kinase mutations. KinaseMD integrates 679 374 somatic mutations, 251 522 network-rewiring events, and 390 460 drug response records curated from various sources for 547 kinases. We uniquely annotate the mutations and kinase inhibitor response in four types of protein substructures (gatekeeper, A-loop, G-loop and αC-helix) that are linked to kinase inhibitor resistance in literature. In addition, we annotate functional mutations that may rewire kinase regulatory network and report four phosphorylation signals (gain, loss, up-regulation and down-regulation). Overall, KinaseMD provides the most updated information on mutations, unique annotations of drug response especially drug resistance and functional sites of kinases. KinaseMD is accessible at https://bioinfo.uth.edu/kmd/, having functions for searching, browsing and downloading data. To our knowledge, there has been no systematic annotation of these structural mutations linking to kinase inhibitor response. In summary, KinaseMD is a centralized database for kinase mutations and drug response.

12 August 2021 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
EMEmily F. Mendez
Emily F. Mendez
HWHaichao Wei
Haichao Wei
RHRuifeng Hu
Ruifeng Hu
LSLaura Stertz
Laura Stertz
Gabriel FriesGabriel Fries
Gabriel Fries
CWConsuelo Walss-Bass
Consuelo Walss-Bass

29 January 2024 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
MDMANIKANDAN DHAYALAN
MANIKANDAN DHAYALAN
WWWei Wang
Wei Wang
SRSU Mohammed Riyaz
SU Mohammed Riyaz
RDRakshi Anuja Dinesh
Rakshi Anuja Dinesh
JSJayashree Shanmugam
Jayashree Shanmugam
RHRuifeng Hu
Ruifeng Hu

2 July 2021 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
ALAndi Liu
Andi Liu
YDYulin Dai
Yulin Dai
EMEmily F Mendez
Emily F Mendez
RHRuifeng Hu
Ruifeng Hu
GFGabriel R Fries
Gabriel R Fries
ZZZhongming Zhao
Zhongming Zhao
Background: Opioid use disorder (OUD) affects millions of people, causing nearly 50 000 deaths annually in the United States. While opioid exposure and OUD are known to cause widespread transcriptomic and epigenetic changes, few studies in human samples have been conducted. Understanding how OUD affects the brain at the molecular level could help decipher disease pathogenesis and shed light on OUD treatment.Methods: We generated genome-wide transcriptomic and DNA methylation profiles of 22 OUD subjects and 19 non-psychiatric controls. We applied weighted gene co-expression network analysis to identify genetic markers consistently associated with OUD at both transcriptomic and methylomic levels. We then performed functional enrichment for biological interpretation. We employed cross-omics analysis to uncover OUD-specific regulatory networks.Results: We found 6 OUD-associated co-expression gene modules and 6 co-methylation modules (false discovery rate <0.1). Genes in these modules are involved in astrocyte and glial cell differentiation, gliogenesis, response to organic substance, and response to cytokine (false discovery rate <0.05). Cross-omics analysis revealed immune-related transcription regulators, suggesting the role of transcription factor-targeted regulatory networks in OUD pathogenesis.Conclusions: Our integrative analysis of multi-omics data in OUD postmortem brain samples suggested complex gene regulatory mechanisms involved in OUD-associated expression patterns. Candidate genes and their upstream regulators revealed in astrocyte, and glial cells could provide new insights into OUD treatment development.